CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 16 enrolled
Drug / intervention
Ethylenediamine dihydrochloride allergen patchdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01798589
NCT01798589Phase 4Completed
CompareCT.gov

Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations

Allerderm·interventional·Posted Feb 26, 2013·Updated Jul 28, 2023

In Brief

A Phase 4 clinical trial evaluating Ethylenediamine dihydrochloride allergen patch for Allergic Contact Dermatitis. Completed, enrolled 16 participants across 1 site.

Detailed Summary

The purpose of this study is to compare the allergen ethylenediamine dihydrochloride when prepared using methylcellulose versus preparation using polyvinylpyrrolidone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Contact Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 26, 2013
Enrollment StartJul 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.3 years ago

Interventions

Ethylenediamine dihydrochloride allergen patchdrug

1 allergen panel containing 2 allergen and 2 control patches